Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28783617 | 0.87 | — | — | |
| SCHEMBL18114281 | 0.82 | — | — | |
| SCHEMBL18114209 | 0.80 | SYK (0.36) | SYKCHRNB2CHRNA4 | |
| SCHEMBL21795752 | 0.80 | MAPT (0.43) | CHRNA7MAPTTSHRKDM4ESMN1; SMN2 | |
| SCHEMBL2178741 | 0.78 | NQO1 (0.39) | NQO1CYP11B1CYP11B2CHRNB2CHRNA4 | |
| SCHEMBL2177255 | 0.78 | NQO1 (0.39) | NQO1CYP11B1CYP11B2CHRNB2CHRNA4 | |
| SCHEMBL18114249 | 0.78 | ALDH1A1 (0.38) | SYKALDH1A1 | |
| SCHEMBL1022718 | 0.78 | — | — | |
| SCHEMBL18114202 | 0.78 | CYP11B1 (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL2178735 | 0.77 | NQO1 (0.38) | NQO1CYP11B1CYP11B2CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111747952-A | Imidazoquinolinones and their use as ATM kinase inhibitors | 默克专利股份公司 | 2020-10-09 | — | — | CN | claimed |
| CN-111689963-A | Imidazoquinolinones and their use as ATM kinase inhibitors | 默克专利股份公司 | 2020-09-22 | — | — | CN | claimed |
| US-20180072715-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2018-03-15 | — | — | US | claimed |
| EP-3277681-A1 | IMIDAZOLONYL QUINOLINES AND USE THEREOF AS ATM KINASE INHIBITORS | Merck Patent GmbH (DE) | 2018-02-07 | — | — | EP | claimed |
| WO-2016155884-A1 | IMIDAZOLONYL QUINOLINES AND USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-10-06 | — | — | WO | claimed |
| US-20230203034-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2023-06-29 | — | — | US | disclosed |
| US-11608338-B2 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | MERCK PATENT GMBH (DE) | 2023-03-21 | — | — | US | disclosed |
| US-20230044248-A1 | COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER | ARES TRADING S.A. (CH) | 2023-02-09 | — | — | US | disclosed |
| EP-4051279-A1 | COMBINED INHIBITION OF PD-1, TGFß AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER | Ares Trading S.A. (CH) | 2022-09-07 | — | — | EP | disclosed |
| CN-114615995-A | Combined inhibition of PD-1, TGF beta and ATM and radiotherapy for cancer treatment | 阿雷斯贸易股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-20210198257-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2021-07-01 | — | — | US | disclosed |
| WO-2021084124-A1 | COMBINED INHIBITION OF PD-1, TGFβ AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER | ARES TRADING S.A. (CH) | 2021-05-06 | — | — | WO | disclosed |
| CN-107889488-B | Imidazoquinolinones and their use as ATM kinase inhibitors | 默克专利股份公司 | 2020-08-11 | — | — | CN | disclosed |
| EP-3560924-A1 | IMIDAZOLONYL QUINOLINES AND THEIR USE AS ATM KINASE INHIBITORS | Merck Patent GmbH (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-10457677-B2 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | MERCK PATENT GMBH (DE) | 2019-10-29 | — | — | US | disclosed |
| US-20190211013-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2019-07-11 | — | — | US | disclosed |
| US-20180072715-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
| EP-3277681-A1 | IMIDAZOLONYL QUINOLINES AND USE THEREOF AS ATM KINASE INHIBITORS | Merck Patent GmbH (DE) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016155884-A1 | IMIDAZOLONYL QUINOLINES AND USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-10-06 | — | — | WO | disclosed |
| US-20110166162-A1 | 1,2-Benzisothiazole Compounds Useful for Combating Animal Pests | BASF SE (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203034-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | NQO1 992/4885CYP11B1 1286/4885CYP11B2 1692/4885 |
| US-20190211013-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | NQO1 992/4885CYP11B1 1286/4885CYP11B2 1692/4885 |
| US-10457677-B2 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | ATM, CHEK2, CHEK1 | NQO1 810/4885CYP11B1 2467/4885CYP11B2 2583/4885 |
| US-20110166162-A1 | 1,2-Benzisothiazole Compounds Useful for Combating Animal Pests | GLRX3, CBR3, PRDX1 | NQO1 1276/4885CYP11B1 3619/4885CYP11B2 3916/4885 |
| US-20230044248-A1 | COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER | ATM, PDCD1, CD274 | NQO1 2946/4885CYP11B1 3801/4885CYP11B2 4354/4885 |
| US-20210198257-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | NQO1 992/4885CYP11B1 1286/4885CYP11B2 1692/4885 |
| US-11608338-B2 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | ATM, CHEK2, CHEK1 | NQO1 992/4885CYP11B1 1286/4885CYP11B2 1692/4885 |
| US-20180072715-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | NQO1 810/4885CYP11B1 2467/4885CYP11B2 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.